<DOC>
	<DOC>NCT01256437</DOC>
	<brief_summary>The investigators hypothesized that topical anti-inflammatory treatment could counteract the inflammatory reaction induced by EGFR'Is.</brief_summary>
	<brief_title>Evaluating Preventive Therapy With Oint Threolone, Synthomycine or Aqua Cream Lotion, for EGFR'I Induced Acneiform Rash</brief_title>
	<detailed_description />
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Patients who are planed to initiate treatment with either cetuximab , erlotinib, gefitinib or panitumumab. Patients who received any facial topical treatment / systemic antibiotics or any antiinflammatory drug during the 2 weeks prior to study initiation. Known hypersensitivity to ointment Synthomycine or to Threolone. Patients presented with cutaneous rash during the 2 weeks prior to study initiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Acneiform eruption</keyword>
	<keyword>papulopustular</keyword>
	<keyword>EGFR</keyword>
	<keyword>cetuximab</keyword>
	<keyword>erlotinib</keyword>
	<keyword>gefitinib</keyword>
	<keyword>panitumumab</keyword>
	<keyword>eruption secondary to treatment with either cetuximab</keyword>
</DOC>